Jorge Saucedo, MD
Cardiovascular Disease · Little Rock, ARNPI 1598734337
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,854 of the $5,675 with a category attached, or 85.5%. B. Braun Interventional Systems Inc. accounts for 93.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $5,019 and has fallen 99.6% since, to $18 in 2025.
Across 21 payments — averaging $270.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- B. Braun Interventional Systems Inc.$5K
- Abbott$153
- Biotronik Inc.$128
- Medtronic$24
- Heartflow, Inc.$23
- Abiomed$18
- plus $54 from 4 others
Across 7 payments — averaging $2411.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$15K
- B. Braun Interventional Systems Inc.$2K
What the payments were for
- Travel & lodging$4,85486%
- Food & beverage$82114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| B. Braun Interventional Systems Inc. | 10 | $5,275 |
| Abbott | 3 | $153 |
| Biotronik Inc. | 1 | $128 |
| Medtronic | 1 | $24 |
| Heartflow, Inc. | 1 | $23 |
| Abiomed | 1 | $18 |
| Novartis | 1 | $17 |
| Boston Scientific | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Asahi Intecc USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CP STENT TRANSCATHETER STENT$4,759
- TYSHAK BALLOON CATHETER$149
- Solia$128
- Rivacor$128
- Edora$128
- BioMonitor$128
- Acticor$128
How this compares
$5,675 in reported general payments places this provider in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $34,814 |
| FarxigaDapagliflozin Propanediol | 23 | $27,163 |
| BrilintaTicagrelor | 12 | $7,124 |
| Losartan Potassium | 65 | $623 |
| Atorvastatin Calcium | 65 | $539 |
| Metoprolol Succinate | 51 | $462 |
| Amlodipine Besylate | 74 | $355 |
| Rosuvastatin Calcium | 30 | $281 |
| Lisinopril | 35 | $236 |
| Carvedilol | 47 | $190 |
| ClopidogrelClopidogrel Bisulfate | 14 | $143 |
| Spironolactone | 18 | $94 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $93 |
| Furosemide | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $12 | $34,28735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.